ProAssurance Co. (NYSE:PRA) Holdings Decreased by Rhumbline Advisers

Rhumbline Advisers trimmed its position in ProAssurance Co. (NYSE:PRA) by 0.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 166,633 shares of the insurance provider’s stock after selling 1,098 shares during the quarter. Rhumbline Advisers owned approximately 0.33% of ProAssurance worth $2,036,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in the company. Victory Capital Management Inc. acquired a new position in ProAssurance during the 4th quarter valued at approximately $141,000. BNP Paribas Financial Markets boosted its position in ProAssurance by 19.5% during the 4th quarter. BNP Paribas Financial Markets now owns 33,764 shares of the insurance provider’s stock valued at $466,000 after purchasing an additional 5,507 shares during the period. Dimensional Fund Advisors LP boosted its position in ProAssurance by 6.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,838,938 shares of the insurance provider’s stock valued at $39,150,000 after purchasing an additional 168,634 shares during the period. Quest Partners LLC acquired a new position in ProAssurance during the 4th quarter valued at approximately $149,000. Finally, Hsbc Holdings PLC boosted its position in ProAssurance by 6.0% during the 4th quarter. Hsbc Holdings PLC now owns 97,624 shares of the insurance provider’s stock worth $1,349,000 after acquiring an additional 5,494 shares during the period. 85.58% of the stock is currently owned by institutional investors.

ProAssurance Stock Up 1.9 %

PRA opened at $13.48 on Friday. ProAssurance Co. has a one year low of $10.76 and a one year high of $19.25. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.26 and a current ratio of 0.26. The stock’s fifty day moving average is $12.72 and its 200-day moving average is $12.99. The company has a market capitalization of $687.64 million, a PE ratio of -24.96 and a beta of 0.23.

ProAssurance (NYSE:PRA) last posted its quarterly earnings data on Thursday, August 8th. The insurance provider reported $0.23 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.15. ProAssurance had a positive return on equity of 0.86% and a negative net margin of 2.00%. The company had revenue of $290.30 million for the quarter, compared to the consensus estimate of $235.61 million. During the same quarter in the previous year, the business earned $0.16 EPS. The company’s quarterly revenue was down .5% compared to the same quarter last year. On average, equities analysts predict that ProAssurance Co. will post 0.58 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on PRA. JMP Securities reduced their price target on ProAssurance from $22.00 to $20.00 and set a “market outperform” rating for the company in a research report on Wednesday, July 17th. Truist Financial reduced their price target on ProAssurance from $16.00 to $14.00 and set a “hold” rating for the company in a research report on Monday, August 12th. Two research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $16.33.

About ProAssurance

ProAssurance Corporation, through its subsidiaries, provides property and casualty insurance, and reinsurance products in the United States. The company operates through Specialty Property and Casualty, Workers’ Compensation Insurance, and Segregated Portfolio Cell Reinsurance segments. It offers professional liability insurance to healthcare providers and institutions, and attorneys and their firms; medical technology liability insurance to medical technology and life sciences companies; and custom alternative risk solutions, including assumed reinsurance, loss portfolio transfers, and captive cell programs for healthcare professional liability insureds.